AbbVie reports ABBV-295 Phase 1 weight loss data
- AbbVie (NYSE:ABBV) reported Phase 1 results for investigational ABBV-295 showing weight reductions across weekly and less frequent dosing schedules.
- Adjusted mean weight changes ranged from 7.8% to 9.8% reductions at Week 12 with weekly dosing and reached 9.7% with every-other-week dosing at Week 13.
- AbbVie stated that it plans to advance ABBV-295 into Phase 2 development for chronic weight management.
AbbVie (NYSE:ABBV) announced Phase 1 results for investigational ABBV-295, reporting adjusted mean weight reductions of up to 9.8% after 12 weeks of weekly dosing in a study involving 60 participants.
The Phase 1 trial evaluated ABBV-295 across weekly, every-other-week and monthly dosing schedules, with weight reductions compared with approximately 0.3% for placebo and participants having a mean body mass index of 29.3 kg/m².
The study showed adjusted mean weight changes of -7.8% to -9.8% at Week 12 with weekly dosing and -9.7% and -7.9% at Week 13 with every-other-week and monthly dosing, respectively, while the drug’s mean half-life ranged from 10.7 to 12.3 days.
AbbVie reported that no serious treatment-emergent adverse events occurred, while nausea was reported in 33.3% of ABBV-295 participants compared with 20.0% for placebo, and diarrhea occurred in 20% compared with 0.0%.
AbbVie is developing ABBV-295 as an investigational therapy for chronic weight management and stated that the program will advance into Phase 2 clinical development.
